Related Experiment Video
Updated: Jan 8, 2026
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Enhancing pneumococcal vaccine efficacy in pediatric patients with asthma: Investigating immune response modulation
Rebekah Brawley1, Andrea Espina Rey1, Aledie Navas Nazario2
1College of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
Insights
Pneumococcal booster vaccines in children with asthma show strong initial protection and improve asthma control. However, immunity wanes over time, indicating a need for optimized vaccine schedules in this high-risk group.
Area of Science:
- Pediatric Pulmonology
- Infectious Disease Immunology
- Vaccinology
Background:
- Pediatric asthma patients face higher risks of invasive pneumococcal disease.
- Optimal pneumococcal vaccination strategies, especially booster doses, for children with asthma are not well-defined.
- Understanding vaccine effectiveness in this population is crucial for public health.
Purpose of the Study:
- To assess the serologic response to pneumococcal booster vaccination in pediatric asthma patients.
- To evaluate clinical outcomes, including asthma severity and steroid use, following vaccination.
- To investigate the durability of immune protection after booster doses.
Main Methods:
- Retrospective chart review of 64 pediatric asthma patients (aged 2-17) who received pneumococcal boosters.
- Collected data on demographics, asthma severity, systemic steroid use, and vaccine titers.
- Analyzed changes in asthma classification and steroid use pre- and post-vaccination.
Main Results:
- 96.9% achieved protective antibody titers 4-8 weeks post-vaccination.
- 71.4% lost protective titers after 6 months, indicating waning immunity.
- Significant reductions in asthma severity (p<0.001) and systemic steroid use (p<0.001) were observed post-vaccination.
Conclusions:
- Pneumococcal booster vaccination provides initial immune protection and improves asthma outcomes in children.
- Waning immunity necessitates further research into optimal vaccine scheduling and timing for boosters.
- Investigating the impact of immunomodulatory therapies on vaccine response is essential.
Objective:
Pediatric patients with asthma are at increased risk for invasive pneumococcal disease, yet optimal vaccination strategies for this population remain unclear. Although pneumococcal vaccines are recommended for high-risk groups, the effectiveness of immunization in children with asthma, particularly regarding booster doses, is not well understood. This study assessed serologic response and clinical outcomes following pneumococcal booster vaccination in pediatric patients with asthma.
Methods:
A retrospective chart review was conducted on 64 patients with asthma aged 2-17 years who received at least one pneumococcal booster. Data on demographics, asthma severity, steroid use, and vaccine titers were collected. Immune protection was defined by serotype-specific titer thresholds. Changes in asthma classification and systemic steroid use pre- and post-vaccination were analyzed using chi-squared tests.
Results:
At 4-8 weeks post-vaccination, 96.9% of patients demonstrated protective antibody titers. However, 71.4% of those retested more than 6 months later lost protective titers, suggesting waning immunity. Statistically significant reductions in asthma severity (p < 0.001) and systemic steroid use (p < 0.001) were observed post-vaccination. Notably, 100% of patients with severe asthma and 46% with moderate asthma improved in classification. Most patients requiring frequent steroids pre-vaccination showed reduced need afterward.
Conclusions:
Pneumococcal booster vaccination elicited a strong initial immune response and was associated with improved asthma outcomes. However, waning immunity highlights the need for further research into optimal vaccine scheduling, booster timing, and the influence of immune-modulating therapies in this high-risk pediatric population.
More Related Videos
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Nursing Management
First, in...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:29Asthma-I: Introduction